v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04537351 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Dec. 1, 2022, 4 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Dec. 1, 2022, 4 p.m. Source : ClinicalTrials.gov |
Not reported |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-09-03 |
Recruitment status
Last imported at : Dec. 1, 2022, 4 p.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Open label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: male or female, 18 years of age or older respiratory failure with the following signs and symptoms: p/f ratio <300 mmhg onset within one week of a known insult or new or worsening respiratory symptoms. chest imaging shows bilateral opacities, which are not fully explained by effusions, lobar/lung collapse, or nodules. respiratory failure which is not fully explained by cardiac failure or fluid overload. onset of respiratory failure within the past 48 hours (as defined in inclusion criterion 2 |
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
- <18 years of age - patient is known to be pregnant - known active malignancy that required treatment in the last year - who class iii or iv pulmonary hypertension - venous thromboembolism currently receiving anti-coagulation or within the past 3 months - currently receiving extracorporeal life support - severe chronic liver disease (child-pugh score >12) - "do not attempt resuscitation" order in place - treatment withdrawal imminent within 24 hours - bmi > 45 kg/m2. - received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. - known positive test for human immunodeficiency virus 1 (hiv 1), hiv 2, hepatitis b virus, hepatitis c virus or any other infection which the opinion of the investigator is likely to impact on the ability of the patient to participate in the study. - known sensitivity to dimethylsulfoxide (dmso) or any other component of the study treatment. |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Cynata Therapeutics Limited |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
100 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Australia |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Severe/critical disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
7: Severe/critical disease at enrollment |
Total sample size
Last imported at : Dec. 1, 2022, 4 p.m. Source : ClinicalTrials.gov |
14 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Sept. 2, 2023, 4 p.m. Source : ClinicalTrials.gov |
Phase 1 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 367, "treatment_name": "Cyp-001", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |